Follow-up of six blood donors highlights the complementary role and limitations of hepatitis C virus antibody and nucleic acid amplification tests

Vox Sanguinis

Volumn 85, Issue 1, 2003, Pages 1-8

  Hyland, Catherine A ^a,b   Seed, C R ^a   Kiely, P ^a   Parker, S ^a   Cowley, N ^a   Bolton, W ^a  

^a AUSTRALIAN RED CROSS BLOOD SERVICE   (Australia)

^b NONE   (Australia)

Author keywords

Blood donor; Hepatitis C; NAT yield

Indexed keywords

HEPATITIS C ANTIBODY; VIRUS RNA;

ANTIBODY SCREENING; ARTICLE; BLOOD DONOR; CHEMOLUMINESCENCE; CONTROLLED STUDY; ENZYME IMMUNOASSAY; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN TISSUE; IMMUNOBLOTTING; NUCLEIC ACID AMPLIFICATION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEROCONVERSION;

ANTIBODIES, VIRAL; BLOOD DONORS; FALSE NEGATIVE REACTIONS; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C; HUMANS; NUCLEIC ACID AMPLIFICATION TECHNIQUES; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; SEROLOGIC TESTS; TIME FACTORS; VIRAL LOAD;

EID: 0038012858     PISSN: 00429007     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1423-0410.2003.00316.x     Document Type: Article

References (18)

1. International Forum: Implementation of donor screening for infectious agents transmitted by blood by nucleic acid technology. Vox Sang 2002; 82:87-111
2. Muller-Breitkreutz K: Results of viral marker screening of unpaid blood donations and probability of window period donations in 1997. EPFA Working Group on Quality Assurance. Vox Sang 2000; 78:149-157
3. Seed CR, Cheng A, Ismay S, Bolton WV, Kiely P, Cobain TJ, Keller AJ: Assessing the accuracy of three viral risk models in predicting the outcome of implementing HIV and HCV NAT donor screening in Australia and the implications for future HBV NAT. Transfusion 2002; 42:1365-1372
4. Stramer S: US NAT yield: where are we after 2 years? Transfus Med 2002; 12:243-253
5. Busch M: Closing the window on viral transmission; in Stramer SL (ed.): Blood Safety in the New Millennium. Bethesda, AABB Press, 2001:33-54
6. Mison LM, Seed CR, Margaritis AR, Hyland C, ARCBS NAT Study Group: Nucleic acid technology (NAT) screening of Australian blood donors for hepatitis C and HIV-1 RNA: comparison of two high throughput testing strategies. Vox Sang 2003; 84:11-19
7. Reesink HW, Cuypers HT, Sjerps MC, Hopman H, Jongerius JM, Molijn MH, van der Poel C, Lelie PN: Minipool screening for HCV-RNA and HIV-RNA by automated extraction, amplification and detection. Transfusion 2001; 41:4S, S6-4S, S030A
8. Roth WK, Seifried E: Yield and future issues of nucleic acid testing. Transfus Clin Biol 2001; 8:282-284
9. Kleinman S, Stramer S, Mimms L, Phelps B, Gallarda J, Fang C, Busch M: Comparison of preliminary observed yield of HCV and HIV minipool (MP) nucleic acid testing (NAT) with predictions from the incidence/window period (INC/WP) model [Abstract]. Transfusion 2000; 40:S6-S030A
10. Grant PR, Sims CM, Krieg-Schneider F, Love EM, Eglin R, Tedder RS: Automated screening of blood donations for hepatitis C virus RNA using the Qiagen BioRobot 9604 and the Roche COBAS HCV Amplicor assay. Vox Sang 2002; 82:169-176
11. Eiras A, Franco E, Hernandez J, Ibarra A, Montoro J, Muncunill J, Planelles D, Souleda S, Sedeno M, Vesga M, Villaescusa R: HCV screening in blood donations using RT-PCR in mini-pool: experience in Spain after 20 months routine use [Abstract]. Transfusion 2001; 41:83S (SP157)
12. Strauss D, de Kessler DI, Valle C, Jayakar H, Katz Y, Rios M, Valinsky JE: HCV nucleic acid amplification testing (NAT): window period case studies [Abstract]. Transfusion 2002; 42:80S
13. Peoples BG, Preston SB, Tzeng JL, Stramer SL, Gifford L, Wissel ME: Prolonged antibody-negative HCV viremia in a US blood donor with apparent HCV transmission to a recipient. Transfusion 2000; 40:1280-1281
14. Durand F, Beauplet A, Marcellin P: Evidence of hepatitis C virus viremia without detectable antibody to hepatitis C virus in a blood donor. Ann Intern Med 2000; 133:74-75
15. Brojer E, Liszewski G, Niznik A, Rosiek A, Letowska M, Peterson JE, Calmann M, Kerrison PL, Lee SR: Detection of HCV core antigen in HCV RNA positive, anti-HCV negative blood donations from Polish blood donors. Transfusion 2001; 41:304
16. Araujo FM, Henriques I, Monteiro F, Meireles E, Koch MC, Celeste R, Cunha-Ribeiro LM: The first case of HCV seroconversion in Portugal after the introduction of HCV NAT screening. Transfusion 2001; 41:848-849
17. Seed CR, Margaritis AR, Bolton WV, Kiely P, Parker S, Piscitelli L: Improved efficiency of national HIV, HCV, and HTLV antibody testing algorithms based on sequential screening immunoassays. Transfusion 2003; 43:226-234
18. Tobler L, McAuley J, Brodsky JP, Spizman R, Gefter N, Pappalardo B, Andrews W, Phelps B, Busch MP: Frequency and significance of very low level viremia in minipool NAT negative hepatitis C (HCV) antibody confirmed positive donors [Abstract]. Transfusion 2002; 42:3S